EGFR and cancer: Our study found that the elevated MSLN in hepatic metastatic TNBC could activate the EGFR as well as downstream ERK1/2 signaling pathways, thereby promoting the ability of cancer cells to survive and proliferate in the liver, and further contributing to the formation of hepatic metastases.